PF-08653944

Overview

What is PF-08653944 and what does the research say?

Identity

Also Known As

Pfizer GLP-1 • Monthly GLP-1

How It Works (Simplified)

PF-08653944 is a long-acting GLP-1 receptor agonist designed for once-monthly subcutaneous administration. Like other GLP-1 receptor agonists, it mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve glycemic control. The monthly dosing interval represents a significant advancement over current weekly injectable options.

Scientific Pathways

GLP-1 Receptor Activation: Binds to and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and activating central satiety pathways in the hypothalamus.

Extended Duration: Pfizer’s proprietary formulation technology enables sustained GLP-1 receptor engagement over approximately 30 days from a single injection, potentially improving treatment adherence compared to weekly alternatives.

Clinical Evidence

Phase 2b Results: The Phase 2b trial demonstrated 12.3% body weight loss at 28 weeks with the highest dose of PF-08653944, with a dose-response relationship across multiple dose levels. The monthly dosing was generally well tolerated.

Phase 3 Program: Pfizer announced plans for 10 Phase 3 trials in 2026, covering obesity, type 2 diabetes, and potentially cardiovascular indications. This represents one of the largest GLP-1 clinical programs in development.

Safety Profile

Phase 2b safety data showed a GI adverse event profile consistent with the GLP-1 class, including nausea, vomiting, and diarrhea. The monthly dosing may result in a different temporal pattern of side effects compared to weekly formulations. Full safety characterization awaits Phase 3 data.

Important Limitations

• Phase 2b only; no Phase 3 data yet available
• Efficacy (12.3% weight loss) lower than leading competitors at similar timepoints
• Monthly injection may limit dose titration flexibility
• Not available outside clinical trials
• Pfizer’s previous GLP-1 candidate (danuglipron) was discontinued, raising execution questions

Peptide Interactions

Known and theoretical interactions when combining PF-08653944 with other peptides. Based on published research and mechanistic considerations.

Synergistic

Compatible

Caution

Avoid

Semaglutide

Avoid

Avoid

Both are GLP-1 receptor agonists. Co-administration would provide redundant GLP-1 agonism with increased risk of GI adverse events.

Tirzepatide

Avoid

Avoid

Both target GLP-1 receptors. Combining would create overlapping mechanisms with potential for severe GI side effects.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

References

8 Sources

5 Human

3 Preclinical

Full reference list available on request. All citations link to PubMed for verification.

Methodology Note

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.